MOTS-c Metabolic Research Brief
This Week: MOTS-c and Metabolic Status
A 2026 observational study reported higher circulating MOTS-c levels in adults with obesity and ...
26
Jul
Blog
26
Jul
MOTS-c and Metabolic Dysregulation Research 2026
MOTS-c obesity research in 2026: what metabolic dysregulation, insulin resistance and mitochondrial signaling evidence reveals.
23
Jul
MOTS-c Legal Status 2026: FDA PCAC
MOTS-c legal status 2026: FDA reclassification, PCAC review, compounding pathway, research-only limits and FAQ.
19
Jul
MOTS-c Muscle Research Brief
A concise MOTS-c research brief covering 2026 muscle preservation/cachexia signals, model-specific interpretation, and research-use catalog links.
19
Jul
MOTS-c Muscle Preservation Research 2026
MOTS-c muscle preservation research: 2026 cachexia findings, mitochondrial mechanisms, sarcopenia context, evidence limits, FAQ.
16
Jul
MOTS-c Heart Health Research 2026
MOTS-c heart health research in 2026: cardiac inflammasome, diabetic rat data, mitochondrial signaling, comparisons, and FAQ.
12
Jul
MOTS-c Research Brief
A concise BioPharma brief on MOTS-c research, this week’s GLP-1 neurology signal, and peptide study interpretation.
12
Jul
BPC-157 Ischemia Research 2026
BPC-157 ischemia research: 2026 Sci Rep vascular protection data, ischemia-reperfusion mechanisms, comparisons, limits, and FAQ.
09
Jul
RFK Peptide Reclassification 2026: Research Guide
RFK peptide reclassification 2026 explained: FDA compounding list context, research impact, evidence limits, compliance, and FAQ.
05
Jul
BPC-157 Cognitive Research Brief
A concise BioPharma brief on BPC-157 cognitive research, MOTS-c catalog context, and peptide study interpretation.